Pricing Log in Create free account
Saturday 17 October 2026 Export FLGT’s income statement to Excel — free account

Fulgent Genetics, Inc.

FLGT Healthcare Diagnostics & Research

Fulgent Genetics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $322.7 million, up 13.8% from fiscal 2024. In the quarter to June 2026, revenue grew 4.38%, EPS fell 69.4% and free cash flow grew 25.4%, each against the same quarter a year earlier.

19.81 1.53 −7.17%
Market cap
$587.2M
P/E
0.0×
Fwd P/E
−5.8×
Dividend yield
—
F-score
4/9
Altman Z
5.63
Beneish M
−2.35
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.68
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell 5 2 — — — — 2 2 — 2 2 —
Insider Ownership 37.12%

Capital & Financial Ratios $m

Market Cap 587.18
Revenue 323.93
Net Income (85.47)
Free Cash Flow (103.78)
Net Debt (257.03)
Current Ratio 6.34 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (5.80) (negative: loss-making)
P/S ratio 1.71
P/B ratio 0.56
Past 5Y EPS Growth —
This Y EPS Growth (640.48%) (below 0%: weak)
Next Y EPS Growth 39.21% (at or above 15%: strong)
Next Y revenue growth 2.80%
Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.0×, against a ten-year median of 1.9×; over the ten years it ranged from 0.4× in 2022 to 14.3× in 2020.
P/S against its own 10 years 11.13%
10-year low 10-year high
P/B against its own 10 years 12.87%
10-year low 10-year high
EV/Sales against its own 10 years 13.86%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2025 Powerpack
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 424 258 336 257
Receivables 51 69 85 65
Inventory — — — —
Other 33 23 23 22
508 354 550 455
2023 2024 2025 Q'26
Payables 15 18 19 16
ST’ Debt — — — —
Other 26 30 32 32
73 73 85 72

Compound Annual Growth %

10y 5y 3y
Sales 42.15% (5.21%) (19.52%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 71.10% 14.22% (4.48%)

Revenue $m

Mar Jun Sep Dec Year
’26 71 85 — — —
’25 73 82 84 83 323
’24 64 71 72 76 283
’23 66 68 85 71 289
’22 320 125 106 68 619
’21 359 154 228 252 993
’20 8 17 102 295 422
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 7 (24) — — —
’25 (4) (30) 11 (78) (102)
’24 7 4 (16) 25 21
’23 (8) 10 10 15 27
’22 188 11 21 33 254
’21 233 76 152 77 539
’20 1 (4) 9 134 141
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 2 (28) — — —
’25 (9) (37) 5 (83) (124)
’24 3 (9) (35) 21 (19)
’23 (10) (2) 5 12 6
’22 183 8 16 29 235
’21 222 73 149 71 515
’20 1 (5) (1) 110 106
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.80) (1.05) — — —
’25 (0.37) (0.62) (0.21) (0.76) (1.97)
’24 (0.45) (0.29) (0.48) (0.19) (1.41)
’23 (0.52) (0.38) (0.44) (4.30) (5.63)
’22 4.93 0.37 0.06 (0.80) 4.63
’21 6.52 2.59 3.93 3.34 16.38
’20 (0.09) 0.14 1.98 6.16 8.91
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 7.59 2.73 3.02 3.17 6.70 53.02 29.01 23.09 16.56 14.57

Analyst estimates 2026–2028

Powerpack
High 12.15 13.90 5.56 16.50 56.53 189.89 101.98 44.09 29.91 31.04
People
People Employees 70 98 123 139 429 645 1,012 1,184 1,313 1,315
Revenue/emp, $m 0.26 0.19 0.17 0.23 0.98 1.54 0.61 0.24 0.22 0.25
Income, $m
Income, $m Revenue 18 19 21 33 422 993 619 289 283 323
Gross margin, % 63.22 54.35 49.90 56.63 78.70 78.29 59.28 36.12 37.82 40.56
EBT (4) (3) (5) 0 292 677 184 (174) (52) (70)
EBT margin, % (24.45) (16.02) (21.71) 1.26 69.17 68.24 29.73 (60.19) (18.33) (21.70)
Net income (5) (3) (6) 0 214 506 142 (175) (44) (62)
Depreciation 1 2 2 2 4 19 37 142 19 19
Per share, $
Per share, $ Revenue 1.33 1.06 1.19 1.74 18.58 33.75 20.57 9.71 9.38 10.48
Earnings (0.31) (0.15) (0.25) (0.02) 9.44 17.25 4.76 (5.63) (1.41) (1.97)
Cash flow 0.32 0.08 (0.04) 0.29 6.20 18.31 8.42 0.91 0.70 (3.30)
Capex (0.28) (0.30) (0.16) (0.06) (1.55) (0.81) (0.61) (0.72) (1.32) (0.73)
Free cash flow 0.05 (0.23) (0.20) 0.23 4.65 17.51 7.81 0.19 (0.63) (4.04)
Book value 3.97 3.05 2.85 4.42 25.09 39.65 42.19 38.05 37.35 35.96
Shares, m 14 18 18 19 23 29 30 30 30 31
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 5.97 5.81 6.48 0.00 0.00 0.00
P/S 8.36 4.01 2.67 7.42 2.80 2.98 1.49 3.02 1.97 2.51
P/B 2.81 1.39 1.11 2.92 2.08 2.54 0.73 0.77 0.49 0.73
EV/Sales 7.22 2.59 1.22 6.63 2.13 2.55 0.67 1.62 1.13 1.53
EV/FCF 210.52 (12.06) (7.40) 49.77 8.52 4.91 1.78 84.22 (16.96) (3.97)
Cash, $m
Cash, $m Operating cash flow 4 1 (1) 6 141 539 254 27 21 (102)
Capex (4) (5) (3) (1) (35) (24) (18) (21) (40) (23)
Free cash flow 1 (4) (4) 4 106 515 235 6 (19) (124)
Balance, $m
Balance, $m Working capital 23 30 37 33 394 507 540 435 281 466
Total debt — — — 0 15 15 15 — — —
Net debt (21) (26) (31) (28) (284) (435) (511) (424) (258) (336)
Shareholders’ equity 54 54 51 83 569 1,166 1,270 1,133 1,129 1,107
Returns, %
Returns, % ROA (16.74) (4.36) (10.09) (0.58) 54.31 51.27 10.76 (12.80) (3.48) (4.97)
ROIC 1.71 (7.86) (15.75) (0.49) 63.62 57.83 14.71 (17.23) (5.30) (7.39)
ROE (17.94) (4.62) (10.65) (0.61) 65.72 58.48 11.77 (13.97) (3.78) (5.41)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Fulgent Genetics, Inc. vs peers in Diagnostics & Research (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
NEO NeoGenomics, Inc. $2.2B — (loss-making) — (loss-making) +11.21% (above 0%: growing) n/m −16.18% (below 0%: shrinking) 45.56% (4.85%) Compare
WGS GeneDx Holdings Corp. $2.1B — (loss-making) — (loss-making) +11.44% (above 0%: growing) n/m −585.59% (below 0%: shrinking) 68.37% (15.25%) Compare
PSNL Personalis, Inc. $1.7B — (loss-making) — (loss-making) +29.96% (above 0%: growing) n/m −123.46% (below 0%: shrinking) 21.21% (150.25%) Compare
OPK OPKO Health, Inc. $1.2B — (loss-making) — (loss-making) +4.32% (above 0%: growing) n/m +46.46% (above 0%: growing) 48.92% (4.26%) Compare
CSTL Castle Biosciences, Inc. $1.0B — (loss-making) — (loss-making) +20.14% (above 0%: growing) n/m −43.33% (below 0%: shrinking) 77.11% (2.96%) Compare
FLGT Fulgent Genetics, Inc. $587.2M — (loss-making) — (loss-making) +4.38% (above 0%: growing) n/m +25.36% (above 0%: growing) 30.07% (42.25%)
MYGN Myriad Genetics, Inc. $416.1M — (loss-making) — (loss-making) −10.51% (below 0%: shrinking) n/m +43.90% (above 0%: growing) 66.60% (20.40%) Compare
BDSX Biodesix, Inc. $260.7M — (loss-making) — (loss-making) +34.18% (above 0%: growing) n/m +72.75% (above 0%: growing) 82.06% (20.06%) Compare
XGN Exagen Inc. $207.4M — (loss-making) — (loss-making) +15.92% (above 0%: growing) n/m +211.34% (above 0%: growing) 61.27% (8.64%) Compare
Median of peers $1.1B — — +13.68% — +13.86% 63.94% (11.94%)

All 52 Diagnostics & Research stocks →

Fulgent Genetics, Inc. (FLGT) key facts

  • Strength: Fulgent Genetics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $322.7 million, up 13.8% from fiscal 2024.
  • Fulgent Genetics, Inc. (FLGT) is a Diagnostics & Research company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, FLGT traded at $19.81, a market capitalization of $587.2 million.
  • Return on equity was −5.41% and debt-to-equity 0.00.
  • Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 5.63 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Fulgent Genetics, Inc. (FLGT) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/FLGT · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com